Furthermore, studies with xenograft models have demonstrated that nab-PTX enhances tumor targeting through gp60 by increasing concentration of paclitaxel in the tumors and that caveolae-mediated HER2 and SPARC expression may be useful biomarkers for determining the anti-tumor effectiveness of taxans [15, 33, 34]. The gene discussed is SPARC; the disease is neoplasm.